0.27
-12.17%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Cosmos Health
From its filings with the US Securities and Exchange Commission
Cosmos Health is based in Thessaloniki, Greece and is incorporated in Nevada. Its shares trade on Nasdaq under the ticker COSM. The SEC classifies its business as wholesale-drugs, proprietaries & druggists' sundries. In the fiscal year to 31 December 2025, it reported revenue of $65.3m and a net loss of $19.1m. At that date it held total assets of $65.5m and shareholders' equity of $18.4m.
Cosmos Health Inc. was incorporated in 2009 in Nevada and is a diversified, vertically integrated global healthcare group, owner of proprietary pharmaceutical and nutraceutical brands, generics, manufacturer and distributor of healthcare products, engaged in research & development of innovative medicines and repurposing drugs as well as operator of a telehealth platform.
As a global company we are harnessing our expertise and stepping up innovation to continue the momentum behind the discovery, delivery, and expanded development of modern pharmaceutical and nutraceutical products.
We operate in the healthcare sector and particularly in the Pharmaceutical and Nutraceutical businesses. We cover vertically several process phases within the abovementioned sectors, such as research & development, manufacturing, marketing, sales and distribution of products and services. More specifically, we operate in generic medicines, nutraceuticals, biocides, medical devices, novel oncology drugs, drug repurposing and telehealth services.
Generic medicines are the pharmaceutical and therapeutic equivalents of branded pharmaceutical products and are generally marketed under their generic (chemical) names rather than by brand names. Typically, a generic drug may not be marketed until the expiration of applicable patent(s) on the corresponding branded product, unless a resolution of patent litigation results in an earlier opportunity to enter the market.
Quoted from its 10-K, filed 15 Apr 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Health Care Providers & Services
- Listed since
- 19 May 2010
- Employees
- 163
- Website
- cosmosholdingsinc.com ↗
- Head office
- 5 AGIOU GEORGIOU, PILEA, THESSALONIKI, J3, 55438
- Incorporated in
- NV
- Classification
- Wholesale-Drugs, Proprietaries & Druggists' Sundries
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. Grigorios SiokasChairman of the Board, Chief Executive Officer, since 2016$2.7m
- Mr. Georgios TerzisChief Financial Officer$761,598
- Mr. Nikos BardakisChief Operating Officer$88,143
- Mr. Theodoros KarkantzosDirector
- Dr. Anastasios AslidisIndependent Director$60,200
- Mr. Suhel BhutawalaIndependent Director$119,607
- Mr. Demetrios DemetriadesIndependent Director, since 2014$30,150
- Mr. John HoidasIndependent Director$68,150
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Cosmos Health Inc. focuses on branded pharmaceuticals and OTC medicines in the US market.
- Amplerissimo Ltd. provides data mining and statistical analysis services to various sectors.
- SkyPharm S.A. trades pharmaceutical products across EU member states.
Weaknesses
- Cosmos Health Inc. has only 163 employees for its global operations.
- Amplerissimo Ltd. offers consulting services but lacks product sales.
- SkyPharm S.A. operates only within the European Union member states.
Opportunities
- Expanding into new markets within the US for branded pharmaceuticals.
- Increasing OTC medicine sales through Amplerissimo's consulting services.
- Growing demand for generic pharmaceuticals in the EU market.
Threats
- Competition from other pharmaceutical distributors in the US market.
- Regulatory changes affecting pharmaceutical imports in the EU.
- Economic downturns impacting healthcare spending in the US.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.